Objectives: To introduce the structure and activities of the Italian Society for Dermatology and Sexually Transmitted Disease (SIDEMAST)

Introduction: The Italian Society for Dermatology and Sexually Transmitted Disease (SIDEMAST) has more than 1000 members, it represents dermatologists at institutional levels, promotes clinical studies (with grants) and registries, organizes regional and national annual congresses and meetings of the subspecialities of Dermatology, including aesthetic dermatology. Sidemast runs a medical journal (the Giornale Italiano di Dermatologia e Venereologia) the has an impact factor of about 1.5.

Materials / method: N/A

Results: N/A

Conclusion: N/A

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: To show the main mistakes and pitfalls of sunscreens' formulation and use and how to improve photo protection

Introduction: In western world there is a growing awareness of photo protection. However the result is paradoxical with a growing incidence (or at best, a lack of decrease) of both melanoma and non-melanoma skin cancer

Materials / method: Chemistry of sunscreen molecules, formulations, misuse and behaviors of peoples under the sun are reviewed

Results: Many sunscreen molecules have serious limitations of chemical stability, spectrum of absorption, efficacy
Formulation deeply affect the photo biological features of the
The consumer is not adequately informed on the methods of application of sunscreens

Conclusion: More attention should be focused on the formulation of sunscreens and to inform consumers on their correct use

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: To provide an overview of topical therapies to prevent keratinocyte carcinoma and premalignancies.

Introduction: Keratinocyte carcinoma and premalignant actinic keratoses have significantly increasing incidence rates in fair skinned populations world wide. The risk of actinic keratoses (AK) and squamous cell carcinoma (SCC) is especially increased in patients with photo damaged skin and field cancerization. An overview of topical and systemic treatments to prevent keratinocyte carcinoma will be provided.

Materials / method: A literature search on topical treatments for AK treatment including photodynamic therapy (PDT), imiquimod, 5-fluoruracil, ingenol mebutate and diclofenac was performed
Systemic therapies or supplements were also reviewed.

Results: Photodynamic therapy is a well-documented treatment for secondary prevention in skin with multiple AK as well as repeated PDT has potential on primary prevention of AK in high risk patients. Imiquimod, 5-fluoruracil and ingenol mebutate were also reported to prevent new AK lesions.
In systemic treatments, acitretin reduces the number of keratotic lesions in transplant recipients although effects are only sustained as long as therapy is continued. More recently, oral supplement with niacin reduced BCC and SCC during treatment.

Conclusion: Topical treatments, especially PDT, can prevent AKs and possibly keratinocyte carcinomas. Systemic acitretin and niacin report lower BCC and SCC incidence during on-going therapy.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: Discuss the relevant non-surgical and adjuvant treatment options for keratinocyte and melanoma skin cancers
Compare the efficacy and success of these different modalities compared to surgery alone
Describe effective ways to incorporate these into practice

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): Skin Cancer Foundation

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): biofrontera

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability